Terms: = Prostate cancer AND CARS, P49589, 833, ENSG00000110619 AND Staging
4 results:
1. Analytical performance validation of aPROMISE platform for prostate tumor burden, index and dominant tumor assessment with 18F-DCFPyL PET/CT. A pilot study.
García Vicente AM; Lucas Lucas C; Pérez-Beteta J; Borrelli P; García Zoghby L; Amo-Salas M; Soriano Castrejón ÁM
Sci Rep; 2024 Feb; 14(1):3001. PubMed ID: 38321201
[TBL] [Abstract] [Full Text] [Related]
2. staging accuracy of MRI of the prostate with special reference to the influence of the time of last ejaculation on the detection of seminal vesicle invasion.
Blasi F; Malouhi A; Cho CH; Nißler D; Berger FP; Grimm MO; Abubrig M; Teichgräber U; Franiel T
Clin Radiol; 2023 May; 78(5):e425-e432. PubMed ID: 36849278
[TBL] [Abstract] [Full Text] [Related]
3. Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time.
Dhondt B; De Bleser E; Claeys T; Buelens S; Lumen N; Vandesompele J; Beckers A; Fonteyne V; Van der Eecken K; De Bruycker A; Paul J; Gramme P; Ost P
World J Urol; 2019 Dec; 37(12):2557-2564. PubMed ID: 30578441
[TBL] [Abstract] [Full Text] [Related]
4. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract] [Full Text] [Related]
